News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Staff Raises Questions About MannKind Corporation (MNKD) Diabetes Device



3/28/2014 7:45:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MannKind Corp. (MNKD:US)’s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said . MannKind’s Afrezza, a powdered form of insulin delivered through an inhaler, would be the company’s first marketed drug, if approved. A Food and Drug Administration staff report today tied the product to a decline in lung function, bronchial spasms similar to asthma and coughing that caused some patients in trials to stop treatment, according to an online document.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at Reuters


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES